Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: A systematic reviewCapsule Summary
Background: Systemic glucocorticoids are first-line treatment options for autoimmune blistering diseases; however, their long-term use is associated with significant toxicities. Objective: To evaluate the side effects of steroid-sparing agents and compare them with those of steroids. Methods: We sea...
Main Authors: | Faith A.P. Zeng, Anna Wilson, MD, BMedRadSc, Tabrez Sheriff, MD, Dedee F. Murrell, MA, BMBCh, MD, FACD, DSc |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-12-01
|
Series: | JAAD International |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666328722000979 |
Similar Items
-
Bullous eczema presenting as bullous pemphigoid-like eruption: A case series
by: George Atteh, BS, et al.
Published: (2021-04-01) -
Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?
by: Roberto Russo, et al.
Published: (2022-06-01) -
Immunoglobulin M bullous pemphigoid: An enigma
by: Rosalie Baardman, MD, et al.
Published: (2020-06-01) -
Evaluation of ELISA BP180 and BP230 Autoantibodies in Blister Fluid and Serum in the Diagnosis of Bullous Pemphigoid
by: Harish Nagarajan, et al.
Published: (2023-01-01) -
Two infants with blistering rashes originating on acral sites as a presenting sign of infantile bullous pemphigoid
by: Brent Folsom, BS, et al.
Published: (2020-06-01)